Secondary Monoclonal Gammopathy of Undetermined Significance after Allogeneic Stem Cell Transplantation in Multiple Myeloma

Abstract

we describe the occurrence of post-transplant MGUS and its association with response, PFS and OS in this group of patients. Methods Patients, definitions, and diagnostic criteria

Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept

“…Similarly, the second LC (23,092 Da) found in AL‐ex11 was likely non‐pathologic. It is known that new MGUS can develop after chemotherapy or stem cell transplantation in patients with multiple myeloma . The 23,092 Da LC is likely the result of a new clone that developed after treatment.…”

Secondary Monoclonal Gammopathy of Undetermined Significance: A Sign Of Cure Or A Harbinger Of Relapse.

“…The types of heavy and lightchain of this M-protein are specific to the myeloma clone.Therefore, it is used as a marker for diagnosis and monitoringof disease and response in MM [2] .…”

“…which account for approximately 10% of the progression [4] . Furthermore, sMGUS not only occurs in MM patients but also after treatment for other hematologic malignancies and even solid organ transplantations19 [2] .…”

“…Progression-free survival (PFS) (A) and overall survival (OS) (B) according to the presence of secondary monoclonal gammopathy of undetermined significance (sMGUS). Kaplan-Meier analysis was used to test the statistical significance of differences between the survival curves[2] .…”

Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis

“…Reactivation of EBV has been implicated in the pathogenesis of monoclonal gammopathy, particularly when T cells are depleted with anti-thymocyte globulin or alemtuzumab, as in stem-cell transplantation. 7 Monoclonal proteins, through their physicochemical properties or via immunological mechanisms, can cause a variety of renal diseases collectively labeled as monoclonal gammopathies of renal significance (MGRS). 8 Although some antiviral drugs have activity against EBV, none has been approved so far for its treatment.…”